IL6 and COVID-19: Canakinumab administration contributes to the rapidly and persistently improved oxygenation degree without serious side reactions.108 IL-6 has been increasingly suggested to be related to cytokine storm as well as COVID-19 pathogenic mechanism.109 Gordon et al.110 found that for critically ill COVID-19 patients receiving organ support at ICUs, tocilizumab (an IL-6 receptor antagonist) treatment could improve patient prognosis (NCT02735707).